Risk‐stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low‐risk endometrial cancer
Wafa Khadraoui(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Gulden Menderes(Yale University), Christina Tierney(Bridgeport Hospital), Sophie H. Chung(Yale University), Masoud Azodi(Yale University), Levent Mutlu(Yale University), Lingeng Lu(Yale Cancer Center), Elena Ratner(Yale University)
Cited by 2
Related Papers
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332
H19 lncRNA alters DNA methylation genome wide by regulating S-adenosylhomocysteine hydrolase
|Nature Communications|2015|271